IsoRay announces first head and neck cancer treated with Cesium-131

IsoRay, Inc., a Richland-based developer of therapies for prostate and other cancers, has announced the first head and neck cancer treated with Cesium-131. Dwight Babcock, IsoRay’s CEO, stated “This is an important development in our strategy to significantly broaden our base beyond prostate cancer. Cesium-131 has unique characteristics for treating many additional cancers such as this new application that provided a minimally invasive treatment option for this patient.”

Update 8/19/09: IsoRay received FDA clearance to market Cesium-131 for treating other cancers — such as those affecting the head, neck and other organs — beyond the current prostate market.

Related external links (will open a new window):

  • IsoRay Announces First Head And Neck Cancer Treated With Cesium-131
    IsoRay – Richland, Wash. – July 27, 2009
  • IsoRay Announces FDA Clearance Supporting Enhanced Loading and Delivery Methods for the Treatment of Lung, Head and Neck, and Other Tumors
    IsoRay – Richland, Wash. – August 18, 2009

    Related WTC links:

  • IsoRay is a WTC client
  • – end of post –

    This entry was posted in Company_and_Client_News, IsoRay, Life_Sciences, Richland, RTD, Southeast. Bookmark the permalink.

    Leave a Reply

    Fill in your details below or click an icon to log in: Logo

    You are commenting using your account. Log Out /  Change )

    Google photo

    You are commenting using your Google account. Log Out /  Change )

    Twitter picture

    You are commenting using your Twitter account. Log Out /  Change )

    Facebook photo

    You are commenting using your Facebook account. Log Out /  Change )

    Connecting to %s